University of Zaragoza, Children’s Hospital Miguel Servet, Instituto de Investigación Sanitaria de Aragón, Unit of Endocrinology, Zaragoza, Spain
University of Tübingen, Children’s Hospital, Clinic of Pediatric Endocrinology, Tübingen, Germany
J Clin Res Pediatr Endocrinol. 2021 Jun 2;13(2):124-135. doi: 10.4274/jcrpe.galenos.2020.2020.0206. Epub 2020 Oct 2.
Assessment and management of children with growth failure has improved greatly over recent years. However, there remains a strong potential for further improvements by using novel digital techniques. A panel of experts discussed developments in digitalization of a number of important tools used by pediatric endocrinologists at the third 360° European Meeting on Growth and Endocrine Disorders, funded by Merck KGaA, Germany, and this review is based on those discussions. It was reported that electronic monitoring and new algorithms have been devised that are providing more sensitive referral for short stature. In addition, computer programs have improved ways in which diagnoses are coded for use by various groups including healthcare providers and government health systems. Innovative cranial imaging techniques have been devised that are considered safer than using gadolinium contrast agents and are also more sensitive and accurate. Deep-learning neural networks are changing the way that bone age and bone health are assessed, which are more objective than standard methodologies. Models for prediction of growth response to growth hormone (GH) treatment are being improved by applying novel artificial intelligence methods that can identify non-linear and linear factors that relate to response, providing more accurate predictions. Determination and interpretation of insulin-like growth factor-1 (IGF-1) levels are becoming more standardized and consistent, for evaluation across different patient groups, and computer-learning models indicate that baseline IGF-1 standard deviation score is among the most important indicators of GH therapy response. While physicians involved in child growth and treatment of disorders resulting in growth failure need to be aware of, and keep abreast of, these latest developments, treatment decisions and management should continue to be based on clinical decisions. New digital technologies and advancements in the field should be aimed at improving clinical decisions, making greater standardization of assessment and facilitating patient-centered approaches.
近年来,儿童生长障碍的评估和管理有了很大的改进。然而,通过使用新的数字技术,仍然有很大的潜力可以进一步提高。一组专家在由德国默克公司(Merck KGaA)资助的第三届 360°欧洲生长和内分泌紊乱会议上讨论了一些儿科内分泌学家使用的重要工具的数字化发展,本综述基于这些讨论。据报道,已经设计出了电子监测和新算法,可以更敏感地转诊矮小症。此外,计算机程序已经改进了诊断编码方式,以便包括医疗保健提供者和政府卫生系统在内的各种群体使用。已经设计出了更安全的创新颅成像技术,这些技术比使用钆造影剂更敏感和准确。深度学习神经网络正在改变骨龄和骨健康评估的方式,比标准方法更客观。通过应用新的人工智能方法来改进预测生长激素(GH)治疗反应的模型,可以识别与反应相关的非线性和线性因素,从而提供更准确的预测。通过应用新的人工智能方法来改进预测生长激素(GH)治疗反应的模型,可以识别与反应相关的非线性和线性因素,从而提供更准确的预测。通过应用新的人工智能方法来改进预测生长激素(GH)治疗反应的模型,可以识别与反应相关的非线性和线性因素,从而提供更准确的预测。通过应用新的人工智能方法来改进预测生长激素(GH)治疗反应的模型,可以识别与反应相关的非线性和线性因素,从而提供更准确的预测。胰岛素样生长因子-1(IGF-1)水平的测定和解释变得更加标准化和一致,以便在不同的患者群体中进行评估,并且计算机学习模型表明,IGF-1 基线标准差评分是 GH 治疗反应最重要的指标之一。参与儿童生长和治疗导致生长障碍的疾病的医生需要了解并跟上这些最新进展,但治疗决策和管理应继续基于临床决策。新的数字技术和该领域的进步应该旨在改善临床决策,使评估更加标准化,并促进以患者为中心的方法。